Home > News > Teva Signs Biotech Deal
March 6th, 2006
Teva Signs Biotech Deal
Abstract:
ApoSense provides a set of small, specially designed molecules for clinical use. The technology from Petah Tikva, Israel-based NST is based on the apoptotic process, or programmed cell death, and the use of molecular nanotechnology concepts.
Source:
redherring.com
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Announcements
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Finding quantum order in chaos May 17th, 2024
Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||